Catalysts / SKYE
Upcoming FDA decisions and readouts we track for Skye Bioscience, each with the filing that announced it.
FreeBioList tracks 1 upcoming catalyst for Skye Bioscience (SKYE, listed on Nasdaq). It concerns RXC008 (Fibrostenotic Crohn’s disease (GI-restricted pan-ROCK inhibitor)).
First on the list: the Phase 2 readout for RXC008 (Fibrostenotic Crohn’s disease (GI-restricted pan-ROCK inhibitor)), shown as H2 2028, but that timing is flagged needs check and the row's note explains why.
The row links to an SEC filing (8-K or 6-K). It is flagged needs check; open the row to read why. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Skye Bioscience SKYE · Nasdaq | RXC008 | Fibrostenotic Crohn’s disease (GI-restricted pan-ROCK inhibitor) | H2 2028 timing unconfirmed |
Phase 2 readout | Needs check | 8-K exhibit 99.1 ↗ | No |
FreeBioList